Cognitive impairment in schizophrenia: The great unmet need

CNS Spectrums

Volumn 20, Issue S1, 2015, Pages 35-39

  Aquila, Ralph ^a,b,d   Citrome, Leslie ^c  

^a Fountain House   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d Sidney Baer Center   (United States)

Author keywords

Cognition; impairment; psychosis; return to functioning; schizophrenia

Indexed keywords

COGNITION ASSESSMENT; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COGNITIVE REMEDIATION THERAPY; DISEASE ASSOCIATION; HUMAN; NEUROBIOLOGY; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; REHABILITATION CARE; REVIEW; SCHIZOPHRENIA; TREATMENT PLANNING; COGNITION DISORDERS; COMPLICATION; PSYCHOLOGY;

COGNITION DISORDERS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84951157926     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285291500070X     Document Type: Review

References (45)

1. Aquila R, Malamud TJ, Sweet T, Kelleher JD. The store front, Fountain House, and the rehabilitation alliance. Med Gen Med. 2006; 8(3): 67.
2. Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005; 57(6): 688-691.
3. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery. Part 1: test selection, reliability and validity. Am J Psychiatry. 2008; 165(2): 203-213.
4. Lindenmayer JP, McGurk SR, Mueser KT, et al. A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatr Serv. 2008; 59(3): 241-247.
5. Chan JY, Hirai HW, Tsoi KK. Can computer-assisted cognitive remediation improve employment and productivity outcomes of patients with severe mental illness? A meta-analysis of prospective controlled trials. J Psychiatr Res. 2015; 68: 293-300.
6. Kaneko Y, Keshavan M. Cognitive remediation in schizophrenia. Clin Psychopharmacol Neurosci. 2012; 10(3): 125-135.
7. McGurk SR, Mueser KT, Xie H, et al. Cognitive enhancement treatment for people with mental illness who do not respond to supported employment: a randomized controlled trial. Am J Psychiatry. 2015; 172(9): 852-861.
8. Kurzban S, Davis L, Brekke JS. Vocational, social, and cognitive rehabilitation for individuals diagnosed with schizophrenia: a review of recent research and trends. Curr Psychiatry Rep. 2010; 12(4): 345-355.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3): 189-198.
10. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4): 695-699.
11. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000; 101(4): 323-329.
12. Nafees B, van Hanswijck de Jonge P, et al. Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. Schizophr Res. 2012; 140(1-3): 71-76.
13. Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001; 27(2): 235-245.
14. Keefe RS, Haig GM, Marder SR, et al. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. In press. DOI: 10.1093/schbul/sbv111.
15. Rosenheck R, Leslie D, Keefe R, et al. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006; 163(3): 411-417.
16. Schonebaum AD, Boyd JK, Dudek KJ. A comparison of competitive employment outcomes for the clubhouse and PACT models. Psychiatr Serv. 2006; 57(10): 1416-1420.
17. Norman C. The Fountain House movement, an alternative rehabilitationmodel for people withmental health problems, members' descriptions of what works. Scand J Caring Sci. 2006; 20(2): 184-192.
18. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009; 35(3): 549-562.
19. Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015; 29(2): 97-115.
20. Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 2012; 37(1): 16-42.
21. Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 2012; 16(1): 27-34.
22. Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SO, Østergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015; 131(3): 185-196.
23. Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses. 2010; 4(3): 189-200.
24. Tsapakis EM, Travis MJ. Glutamate and psychiatric disorders. Adv Psychiatr Treat. 2002; 8(3): 189-197.
25. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003; 40(5): 881-884.
26. Kantrowitz JT, Javitt DC. Glutamate: new hope for schizophrenia treatment. Curr Psychiatry. 2011; 10(4): 69-74.
27. Citrome L. Neurochemical models of schizophrenia: transcending dopamine. Curr Psychiatry. 2011; 10(9): S10-S14.
28. Stahl MS. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd ed. New York: Cambridge University Press; 2008.
29. Kantrowitz JT, Javitt DC. N-Methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010; 83(3-4): 108-121.
30. Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry. 2014; 75(Suppl 1): 21-26.
31. Iwata Y, Nakajima S, Suzuki T, et al. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. In press. DOI: 10.1038/mp.2015.68.
32. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1): CD005593.
33. Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev. 2012; 1: CD007967.
34. Young JW, Geyer MA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol. 2013; 86(8): 1122-1132.
35. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl). 2006; 184(3-4): 523-539.
36. Huang M, Felix AR, Flood DG, et al. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl). 2014; 231(23): 4541-4551.
37. Prickaerts J, van Goethem NP, Chesworth R, et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology. 2012; 62(2): 1099-1110.
38. Keefe RS, Meltzer HA, Dgetluck N, et al. Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology. In press. DOI: 10.1038/npp.2015.176.
39. Deardorff WJ, Shobassy A, Grossberg GT. Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication. Expert Rev Neurother. 2015; 15(1): 7-17.
40. Forum Pharmaceuticals. FORUM Pharmaceuticals Inc. Updates Encenicline Phase 3 Clinical Trial Programs in Alzheimer's Disease and Cognitive Impairment in Schizophrenia. Press Release. 14 September 2015. Available at: http://www.businesswire.com/news/home/20150914005855/en/FORUM-Pharmaceuticals-Updates-Encenicline-Phase-3-Clinical. Accessed 15 September 2015.
41. Carruthers SP, Gurvich CT, Rossell SL. The muscarinic system, cognition and schizophrenia. Neurosci Biobehav Rev. 2015; 55: 393-402.
42. Köster LS, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014; 19(4): 511-531.
43. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004; 56(5): 301-307.
44. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007; 33(5): 1120-1130.
45. Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011; 99(2): 245-253.